The evaluation of outcomes relate firstly to scale-up and secondly to treatment-as-prevention (TasP). For scale-up the outcome analysis should consider the rate of uptake and completion of the care cascade prior to implementation with the rate following implementation – particularly, increases in the number of prisoners diagnosed with chronic hepatitis C and initiated on DAA treatment.

For the TasP outcome, the analysis should examine whether there has been a reduction in the number and rate of new infections (including primary and reinfections) associated with the scale-up of hepatitis C testing and treatment.